Cost-Effectiveness Analysis Comparing Liposomal Anthracyclines in the Treatment of AIDS-Related Kaposi's Sarcoma

Liposomal formulations have been shown to alter the efficacy and toxicity profiles of anthracylines for patients with HIV-related advanced Kaposi's sarcoma (KS). Using decision-analysis models, the costs and cost-effectiveness of the two U.S. Food and Drug Administration (FDA)-approved liposomal for... View More